FindTrial
Sign In

MSDC-0602K

DRUG2 trials

Sponsors

Cirius Therapeutics, Inc.

Conditions

NASH - Nonalcoholic SteatohepatitisNon-Alcoholic Fatty Liver DiseaseNon-alcoholic Fatty Liver DiseaseNon-alcoholic SteatohepatitisNonalcoholic SteatohepatitisType2 Diabetes

Phase 2

A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH
CompletedNCT02784444
Cirius Therapeutics, Inc.NASH - Nonalcoholic Steatohepatitis, Non-alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis
Start: 2016-09-14End: 2019-06-30Updated: 2020-09-16

Phase 3

A Study of MSDC-0602K to Assess Glycemic Control and Cardiovascular Outcomes in Patients With Pre-T2D or T2D and NAFLD/NASH
NCT03970031
Cirius Therapeutics, Inc.NASH - Nonalcoholic Steatohepatitis, Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis +1
Start: 2022-06-30End: 2024-09-30Target: 1800Updated: 2021-07-12

Related Papers

<scp>ECM</scp> Biomarkers <scp>PRO</scp>‐<scp>C3</scp> and <scp>PRO</scp>‐<scp>C6</scp> Reveal the Anti‐Fibrotic Effect of the Insulin Sensitizer <scp>MSDC</scp>‐0602 K During <scp>EMMINENCE</scp> Randomised Clinical Trial
Liver international communications.2025-04-08
AI-based automation of enrollment criteria and endpoint assessment in clinical trials in liver diseases.
2024-08-0728 citations
1582-P: Fasting Insulin as an Independent Predictor of Metabolic Dysfunction–Associated Steatohepatitis (MASH) Severity
Diabetes2024-06-14
Mitochondrial pyruvate carrier inhibition initiates metabolic crosstalk to stimulate branched chain amino acid catabolism.
2023-02-1845 citations
213-LB: Mechanisms of Metabolic Cross Talk between Mitochondrial Pyruvate Carrier Inhibition and Branched-Chain Amino Acid Catabolism in Hepatocytes
Diabetes2021-06-01
Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study.
2019-11-04176 citations